Sleep-Disordered Breathing and Cardiovascular Disease
2003; Lippincott Williams & Wilkins; Volume: 108; Issue: 1 Linguagem: Inglês
10.1161/01.cir.0000072346.56728.e4
ISSN1524-4539
AutoresRobert Wołk, Tomáš Kára, Virend K. Somers,
Tópico(s)Chronic Obstructive Pulmonary Disease (COPD) Research
ResumoHomeCirculationVol. 108, No. 1Sleep-Disordered Breathing and Cardiovascular Disease Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBSleep-Disordered Breathing and Cardiovascular Disease Robert Wolk, Tomas Kara and Virend K. Somers Robert WolkRobert Wolk From the Mayo Clinic, Rochester, Minn. Search for more papers by this author , Tomas KaraTomas Kara From the Mayo Clinic, Rochester, Minn. Search for more papers by this author and Virend K. SomersVirend K. Somers From the Mayo Clinic, Rochester, Minn. Search for more papers by this author Originally published8 Jul 2003https://doi.org/10.1161/01.CIR.0000072346.56728.E4Circulation. 2003;108:9–12Sleep apnea is defined as repetitive episodes of decreased or total cessation of respiratory airflow during sleep, leading to a fall in oxygen saturation of ≥4% and sleep fragmentation. Sleep apnea can be central or obstructive. Central sleep apnea (CSA) is characterized by apneas secondary to diminution or cessation of thoraco-abdominal respiratory movements (due to dysfunction of central respiratory control mechanisms). Obstructive sleep apnea (OSA) is caused by upper airway collapse during inspiration and is accompanied by strenuous breathing efforts. When defined as >5 episodes of apnea or hypopnea per hour of sleep, OSA is relatively common, affecting 24% and 9% of middle-aged men and women, respectively.1 CSA is primarily seen in patients with congestive heart failure (CHF), although it occasionally may occur in healthy normal subjects, in people at high altitudes, and in association with central neural lesions. Sleep apnea constitutes a major public health problem because of its high prevalence and its emerging association with cardiovascular morbidity.Central Sleep ApneaCSA is especially relevant to CHF. The prevalence of CSA in CHF patients is dependent on various factors, such as heart failure etiology, gender, age, ejection fraction, and hemodynamic status, and has been estimated at 40% to 60%.2,3 Cheyne-Stokes respiration occurs during CSA and is a distinct pattern of periodic breathing with alternating crescendo-decrescendo sequences of hyperventilation and apnea (ie, complete breathing cessation).CSA may have an important influence on prognosis, in that its presence is associated with increased mortality in CHF patients.3 This effect appears to be independent of other known risk factors, such as left ventricular ejection fraction or peak oxygen consumption.Although the association of CSA with CHF has been recognized for decades, it is unclear whether CSA directly affects CHF pathophysiology and can therefore be causally linked to prognosis, or whether it is rather an index of the severity of CHF. Evidence implicating CSA in CHF progression includes the fact that CSA in CHF is associated, first, with increased sympathetic nerve activity, higher urinary and plasma norepinephrine concentration, and perhaps elevated endothelin. Elevated catecholamine and endothelin levels are associated with poorer prognosis in CHF. Second, CSA may also be highly prevalent in patients with asymptomatic left ventricular dysfunction, where it is associated with impaired cardiac autonomic control and increased cardiac arrhythmias, suggesting that CSA may precede the development of overt heart failure. Third, prevention of CSA by continuous positive airway pressure (CPAP) may contribute to improved outcome in CHF. On the other hand, CHF patients with CSA are characterized by lower exercise capacity and ejection fraction, increased left ventricular volumes, elevated pulmonary capillary wedge pressure, and a higher prevalence of cardiac arrhythmias. Therefore, CSA may indeed also be an index of more severe CHF. The most likely scenario is that CHF predisposes to CSA and, in turn, CSA contributes to CHF progression.TreatmentHemodynamic improvement after pharmacological therapy of CHF is often associated with a significant decrease in CSA. However, persistent CSA despite optimal pharmacological therapy (especially if accompanied by severe oxygen desaturation and refractory CHF) should be treated more aggressively. CPAP therapy has been found to improve ejection fraction in CHF patients with CSA and has been associated with a tendency to enhanced transplant-free survival (Figure 1).4 Other therapies, such as theophylline or nocturnal oxygen supplementation, have been shown to decrease the severity of CSA, but their effects on long-term prognosis are not known. Download figureDownload PowerPointFigure 1. Transplant-free survival in CHF patients with CSA treated (and compliant) or not treated with CPAP. The difference was not significant (P=0.1) in intention-to-treat analysis. CPAP also increased ejection fraction. Reprinted with permission from reference 4.The efficacy of CPAP in CHF patients with CSA might be related to a decrease in the obstructive component accompanying CSA or may be due to some direct hemodynamic effects of CPAP. An intriguing finding is that overdrive atrial pacing may decrease CSA in selected patients with symptomatic sinus bradycardia and might perhaps also be related to improved hemodynamics.Obstructive Sleep ApneaOSA has been associated with several cardiovascular diseases, most notably hypertension, ischemic heart disease, heart failure, stroke, cardiac arrhythmias, and pulmonary hypertension. With the exception of hypertension, evidence implicating OSA in these disease conditions is presently circumstantial, and cause-effect relationships remain to be proven.HypertensionThe evidence supporting the causal association between OSA and hypertension is compelling. The Wisconsin Sleep Cohort Study prospectively demonstrated a dose-response association between sleep-disordered breathing at baseline and the presence of hypertension 4 years later.5 This association was independent of other known risk factors, such as baseline hypertension, body mass and habitus, age, gender, and alcohol and cigarette use.The mechanisms underlying the hypertensive effects of OSA are multifactorial. Nocturnal chemoreflex activation by hypoxia and hypercapnia, with consequent sympathetic activation and increased blood pressure (Figure 2),6 might carry over into excessive sympathetic activity and higher blood pressure even during daytime normoxia. Chemoreceptor resetting and tonic chemoreceptor activation may also contribute to daytime increases in sympathetic activity and blood pressure. Patients with OSA also have endothelial dysfunction, increased endothelin, and lower nitric oxide levels, all of which would potentiate vasoconstriction. Download figureDownload PowerPointFigure 2. Recordings of the electrooculogram (EOG), electroencephalogram (EEG), electromyogram (EMG), electrocardiogram (EKG), sympathetic nerve activity (SNA), respiration (RESP), and blood pressure (BP) in a patient with OSA during rapid eye movement sleep. BP surges at the end of the apneic periods. Reprinted with permission from reference 6.Ischemic Heart DiseaseThe clinical importance of OSA in ischemic heart disease is twofold. First, epidemiological evidence supports the concept of OSA being etiologically linked to the development of atherosclerosis. There is a high prevalence of OSA in patients with coronary artery disease, and several case-control or prospective studies suggest OSA as an independent predictor of coronary artery disease. Although the exact mechanisms of any atherogenic effects of OSA have not been established, one intriguing possibility is the involvement of inflammatory processes. C-reactive protein (CRP), a biomarker of systemic inflammation and of an increased risk for coronary events, may also play a direct role in atherogenesis. CRP is elevated in OSA,7 a finding that supports the role of inflammation as a mechanism of OSA-related atherogenesis. Consistent with this hypothesis, elevated plasma levels and cell expression of several adhesion molecules, as well as evidence of increased oxidative stress, have also been noted in OSA.Second, there is evidence that, in patients with or without a history of coronary artery disease, OSA may trigger acute nocturnal cardiac ischemia with ST-segment depression that is often resistant to traditional therapy. Several OSA-related mechanisms, such as oxygen desaturation, high sympathetic activity, increased cardiac oxygen demand (due to tachycardia and increased systemic vascular resistance), and a prothrombotic state, may contribute to the onset of these ischemic episodes. Whether the same mechanisms may also lead to coronary plaque rupture and an acute coronary event remains to be established.Heart FailureOSA has also been reported in association with CHF, with a prevalence up to 11%.2 Soft tissue edema (which would increase while supine during sleep) and consequent increased airway resistance may lead to increased inspiratory force and collapse of the upper airway, thus increasing the risk of new-onset OSA. Conversely, epidemiological data suggest that, independent of other risk factors, OSA is associated with an increased risk for CHF.8 OSA could predispose to CHF by virtue of its effects on sympathetic drive, endothelin, endothelial function, hypertension, and ischemic heart disease, which are known to be important risk factors for CHF. Moreover, OSA may potentiate acute ventricular dysfunction by increasing transmural pressures and ventricular wall stress. The coexistence of CHF and OSA may therefore create a vicious cycle of progressing CHF, with OSA causing deterioration of cardiac function, and with subsequent exacerbation of OSA.StrokeThe prevalence of OSA is increased in patients with stroke, but it is debatable as to what extent stroke-induced breathing abnormalities contribute to this association. The factors that may increase the risk of stroke in OSA include blood flow reduction with individual apnea episodes (caused by negative intrathoracic pressures and increased intracranial pressure), a prothrombotic state, atherosclerosis, and hypertension. From a clinical standpoint, it is an important observation that OSA in stroke survivors may be associated with increased mortality and a worsened long-term functional outcome.Pulmonary HypertensionSome preliminary studies have suggested the presence of mild-to-moderate daytime pulmonary hypertension (and even right ventricular failure) in OSA patients in the absence of lung and heart disease. In some studies, pulmonary hypertensive OSA subjects tended to have a greater body mass and lower daytime arterial oxygen saturation compared with those without pulmonary hypertension, so that some contribution of the obesity-hypoventilation syndrome to elevated pulmonary pressures in OSA cannot be excluded.Cardiac ArrhythmiasThe most frequent arrhythmias reported in association with OSA are sinus arrest, sinoatrial block, or atrioventricular block, all of which may lead to ventricular asystole. The mechanism of these bradyarrhythmias is usually a reflex increase in vagal tone triggered by a combination of apnea and hypoxemia (diving reflex). Therefore, before pacemaker therapy is recommended in patients with nocturnal bradyarrhythmias, the diagnosis of OSA should first be considered and, if present, CPAP therapy should be tried. Because OSA patients sometimes fall asleep during the day, even daytime bradyarrhythmias could be attributed to sleep apnea.Several reports also suggest that OSA may be associated with both supraventricular and ventricular tachyarrhythmias, although the latter are more likely to occur in the setting of other cardiac comorbidities, such as ischemic heart disease or heart failure.TreatmentBehavioral and lifestyle modifications, such as weight loss, avoidance of sedatives and alcohol, and avoidance of sleeping on the back, will often attenuate OSA severity.The treatment of choice in OSA is CPAP. Although it is generally accepted that patients with moderate to severe OSA and daytime somnolence should be treated with CPAP, less clear is whether or not to treat mild OSA in the absence of daytime somnolence. In the short-term, effective CPAP treatment (ie, treatment associated with a significant reduction in apnea severity) may reduce systemic (Figure 3)9 and pulmonary pressures, prevent nocturnal ST-segment depression, improve left ventricular ejection fraction and functional class, and decrease cardiac arrhythmias10 in patients with CHF. Treatment for OSA has also been shown to reduce the risk for motor vehicle accidents, probably by lessening daytime somnolence. However, no clear data showing long term benefit with regard to cardiovascular end points with CPAP therapy are presently available. Download figureDownload PowerPointFigure 3. Changes in blood pressure with effective (closed bars) and subtherapeutic (open bars) CPAP in patients with OSA (*P<0.05). MAP indicates mean arterial pressure. Reprinted with permission from reference 9.Conclusions and RecommendationsThere is strong evidence for an association between sleep apnea and cardiovascular diseases, particularly OSA and hypertension. For other cardiovascular diseases, the evidence, although suggestive, remains circumstantial.Although the comprehensive diagnosis and treatment of OSA and CSA is determined by overnight polysomnography, a history of witnessed apneas during sleep, daytime somnolence, and evidence of oxygen desaturation on overnight oximetry should heighten the index of suspicion for significant sleep apnea.OSA should be considered in patients with refractory hypertension, particularly in obese subjects without the expected nocturnal decline in blood pressure, and in patients with nocturnal cardiac ischemia, nocturnal arrhythmias, and stroke. Both OSA and CSA should be considered in CHF patients who are poorly responsive to conventional treatment.FootnotesCorrespondence to Virend Somers, MD, PhD, Divisions of Cardiovascular Diseases and Hypertension, Department of Medicine, Mayo Foundation, 200 First St SW, Rochester, MN 55902. E-mail [email protected] References 1 Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328: 1230–1235.CrossrefMedlineGoogle Scholar2 Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation. 1998; 97: 2154–2159.CrossrefMedlineGoogle Scholar3 Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation. 1999; 99: 1435–1440.CrossrefMedlineGoogle Scholar4 Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation. 2000; 102: 61–66.LinkGoogle Scholar5 Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342: 1378–1384.CrossrefMedlineGoogle Scholar6 Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96: 1897–1904.CrossrefMedlineGoogle Scholar7 Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002; 105: 2462–2464.LinkGoogle Scholar8 Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Am J Respir Crit Care Med. 2001; 163: 19–25.CrossrefMedlineGoogle Scholar9 Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003; 107: 68–73.LinkGoogle Scholar10 Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation. 2000; 101: 392–397.CrossrefMedlineGoogle Scholar eLetters(0) eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate. Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page. Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Tondo P, Scioscia G, Sabato R, Leccisotti R, Hoxhallari A, Sorangelo S, Mansueto G, Campanino T, Carone M, Foschino Barbaro M and Lacedonia D (2023) Mortality in obstructive sleep apnea syndrome (OSAS) and overlap syndrome (OS): The role of nocturnal hypoxemia and CPAP compliance, Sleep Medicine, 10.1016/j.sleep.2023.10.011, 112, (96-103), Online publication date: 1-Dec-2023. Tubek S, Niewinski P, Langner-Hetmanczuk A, Jura M, Kuliczkowski W, Reczuch K and Ponikowski P (2023) The effects of P2Y12 adenosine receptors’ inhibitors on central and peripheral chemoreflexes, Frontiers in Physiology, 10.3389/fphys.2023.1214893, 14 Nielsen S, Nyvad J, Christensen K, Poulsen P, Laugesen E, Grove E and Buus N (2023) Obstructive sleep apnea, coronary calcification and arterial stiffness in patients with diabetic kidney disease, Atherosclerosis, 10.1016/j.atherosclerosis.2023.06.076, (117170), Online publication date: 1-Jun-2023. Huang Y, Chen K and Zhang Z (2023) Domain - Aware Spatial-Temporal Graph Convolutional Network for Sleep Apnea Detection via Multivariant BCG Signals ICC 2023 - IEEE International Conference on Communications, 10.1109/ICC45041.2023.10278967, 978-1-5386-7462-8, (5515-5520) Huang J, Lian N, Lin G, Xie H, Wang B, Chen G and Lin Q (2023) Expression alteration of serum exosomal circular RNAs in obstructive sleep apnea patients with acute myocardial infarction, BMC Medical Genomics, 10.1186/s12920-023-01464-4, 16:1 Pan W, Xia L, Liu L, Gu L, Xiang M, Zhang H, Wei X, Yang Z, Zhou X, Li J, Zeng D and Jiang J (2022) Increased diastolic blood pressure and apnea time contribute to the poor apnea and hypopnea index and life quality of primary snoring: a cohort study combined with external validation, Sleep and Biological Rhythms, 10.1007/s41105-022-00402-8, 20:4, (561-568), Online publication date: 1-Oct-2022. Huhtakangas J, Saaresranta T, Vähänikkilä H and Huhtakangas J (2022) Nocturnal hypoxemia and central apneas increase mortality, but not recurrent ischemic events after ischemic stroke, Sleep Medicine, 10.1016/j.sleep.2022.05.014, 97, (1-9), Online publication date: 1-Sep-2022. Najafi A, Mohammadi I, Sadeghi M, Brühl A, Sadeghi-Bahmani D and Brand S (2022) Evaluation of Plasma/Serum Adiponectin (an Anti-Inflammatory Factor) Levels in Adult Patients with Obstructive Sleep Apnea Syndrome: A Systematic Review and Meta-Analysis, Life, 10.3390/life12050738, 12:5, (738) Ainge‐Allen H, Yee B and Grunstein R (2022) Obstructive Sleep Apnea Clinical Obesity in Adults and Children, 10.1002/9781119695257.ch15, (192-210), Online publication date: 11-Mar-2022. Huang Y, Huang S, Chung R, Wang B, Chung C, Chien W, Sun C, Yu P and Lu C (2022) Obese Patients Experience More Severe CSA than Non-Obese Patients, International Journal of Environmental Research and Public Health, 10.3390/ijerph19031289, 19:3, (1289) Duss S, Brill A, Baillieul S, Horvath T, Zubler F, Flügel D, Kägi G, Benz G, Bernasconi C, Ott S, Korostovtseva L, Sviryaev Y, Salih F, Endres M, Tamisier R, Gouveris H, Winter Y, Denier N, Wiest R, Arnold M, Schmidt M, Pépin J and Bassetti C (2021) Effect of early sleep apnoea treatment with adaptive servo-ventilation in acute stroke patients on cerebral lesion evolution and neurological outcomes: study protocol for a multicentre, randomized controlled, rater-blinded, clinical trial (eSATIS: early Sleep Apnoea Treatment in Stroke), Trials, 10.1186/s13063-020-04977-w, 22:1, Online publication date: 1-Dec-2021. Qin H, Steenbergen N, Glos M, Wessel N, Kraemer J, Vaquerizo-Villar F and Penzel T (2021) The Different Facets of Heart Rate Variability in Obstructive Sleep Apnea, Frontiers in Psychiatry, 10.3389/fpsyt.2021.642333, 12 Kaur S and Mehra R (2021) Obstructive and Central Sleep Apnea Treatment Challenges in Atrial Fibrillation Complex Sleep Breathing Disorders, 10.1007/978-3-030-57942-5_4, (41-53), . Resano-Barrio M, Arroyo-Espliguero R, Viana-Llamas M and Mediano O (2020) Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk, European Cardiology Review, 10.15420/ecr.2020.10, 15 Huang K, Chen Y, Tseng C, Chang H, Su M, Wang T, Lin Y, Zheng Y, Chang J, Chin C, Hsiao C, Lin M and Wang H (2020) Aberrant DNA methylation of the toll-like receptors 2 and 6 genes in patients with obstructive sleep apnea, PLOS ONE, 10.1371/journal.pone.0228958, 15:2, (e0228958) Huhtakangas J, Saaresranta T, Bode M, Bloigu R and Huhtakangas J (2019) Stroke Volume Predicts Nocturnal Hypoxemia in the Acute Ischemic Stroke after Intravenous Thrombolysis, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2019.06.017, 28:9, (2481-2487), Online publication date: 1-Sep-2019. Afzal A, Tecson K, Jamil A, Felius J, Garcha P, Hall S and Carey S (2019) The Effect of Obstructive Sleep Apnea on 3-Year Outcomes in Patients Who Underwent Orthotopic Heart Transplantation, The American Journal of Cardiology, 10.1016/j.amjcard.2019.04.005, 124:1, (51-54), Online publication date: 1-Jul-2019. Cundrle I, Olson L and Johnson B (2019) Pulmonary Limitations in Heart Failure, Clinics in Chest Medicine, 10.1016/j.ccm.2019.02.010, 40:2, (439-448), Online publication date: 1-Jun-2019. Khalyfa A and Gozal D (2018) Connexins and Atrial Fibrillation in Obstructive Sleep Apnea, Current Sleep Medicine Reports, 10.1007/s40675-018-0130-7, 4:4, (300-311), Online publication date: 1-Dec-2018. Li L, Tang X, Kim S, Zhang Y, Li Y, Fu P and Gołębiewska J (2018) Effect of nocturnal hemodialysis on sleep parameters in patients with end-stage renal disease: a systematic review and meta-analysis, PLOS ONE, 10.1371/journal.pone.0203710, 13:9, (e0203710) Mahajan S, Gupta K, Sinha S, Malhotra A and Mahajan S (2018) Effect of kidney transplantation on sleep-disordered breathing in patients with End Stage Renal Disease: a polysomnographic study, Sleep Medicine, 10.1016/j.sleep.2017.11.1151, 45, (140-145), Online publication date: 1-May-2018. Lin C, Ho C, Tsai W and Chen J (2018) Different effects of apnea during rapid eye movement period on peripheral arterial stiffness in obstructive sleep apnea, Atherosclerosis, 10.1016/j.atherosclerosis.2018.01.008, 269, (166-171), Online publication date: 1-Feb-2018. Tripathy R and Rajendra Acharya U (2018) Use of features from RR-time series and EEG signals for automated classification of sleep stages in deep neural network framework, Biocybernetics and Biomedical Engineering, 10.1016/j.bbe.2018.05.005, 38:4, (890-902), . Gallego P (2018) Co-morbidities Heart Failure in Adult Congenital Heart Disease, 10.1007/978-3-319-77803-7_5, (73-94), . Ludka O, Stepanova R, Sert-Kuniyoshi F, Spinar J, Somers V and Kara T (2017) Differential likelihood of NSTEMI vs STEMI in patients with sleep apnea, International Journal of Cardiology, 10.1016/j.ijcard.2017.06.034, 248, (64-68), Online publication date: 1-Dec-2017. Barón A and Paez-Moya S (2017) Repercusiones cardiovasculares del síndrome de apnea-hipopnea obstructiva del sueño (SAHOS), Revista de la Facultad de Medicina, 10.15446/revfacmed.v65n1Sup.59666, 65:1Sup, (39-46) Hidalgo-Martínez P and Lobelo R (2017) Epidemiología mundial, latinoamericana y colombiana y mortalidad del síndrome de apnea-hipopnea obstructiva del sueño (SAHOS), Revista de la Facultad de Medicina, 10.15446/revfacmed.v65n1Sup.59565, 65:1Sup, (17-20) Morrison S, Mirnik D, Korsic S, Eiken O, Mekjavic I and Dolenc-Groselj L (2017) Bed Rest and Hypoxic Exposure Affect Sleep Architecture and Breathing Stability, Frontiers in Physiology, 10.3389/fphys.2017.00410, 8 Jiang J, Chen X, Zhang C, Wang G, Fang J, Ma J and Zhang J (2016) Heart rate acceleration runs and deceleration runs in patients with obstructive sleep apnea syndrome, Sleep and Breathing, 10.1007/s11325-016-1437-6, 21:2, (443-451), Online publication date: 1-May-2017. Faulk K, Shell B, Nedungadi T and Cunningham J (2017) Role of angiotensin-converting enzyme 1 within the median preoptic nucleus following chronic intermittent hypoxia, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00472.2016, 312:2, (R245-R252), Online publication date: 1-Feb-2017. Roubille F, Fischer K, Guensch D, Tardif J and Friedrich M (2017) Impact of hyperventilation and apnea on myocardial oxygenation in patients with obstructive sleep apnea – An oxygenation-sensitive CMR study, Journal of Cardiology, 10.1016/j.jjcc.2016.03.011, 69:2, (489-494), Online publication date: 1-Feb-2017. Wang M, Ding H, Kang J, Hu K, Lu W, Zhou X and Xu L (2016) Association between polymorphisms of the HSPB7 gene and Cheyne–Stokes respiration with central sleep apnea in patients with dilated cardiomyopathy and congestive heart failure, International Journal of Cardiology, 10.1016/j.ijcard.2016.07.107, 221, (926-931), Online publication date: 1-Oct-2016. Wannamethee S, Papacosta O, Lennon L and Whincup P (2016) Self‐Reported Sleep Duration, Napping, and Incident Heart Failure: Prospective Associations in the British Regional Heart Study, Journal of the American Geriatrics Society, 10.1111/jgs.14255, 64:9, (1845-1850), Online publication date: 1-Sep-2016. Xu P (2016) Association of Obstructive Sleep Apnea with Incidence of Serious Cardiovascular Events in the Elderly: A Meta-analysis, International Journal of Gerontology, 10.1016/j.ijge.2015.12.004, 10:3, (164-169), Online publication date: 1-Sep-2016. Puri R, Athanassiadis A, Gill N, Sathya S, Rathod G, Wahi A, Satat G, Majmudar M and Shah P (2016) Design and preliminary evaluation of a wearable device for mass-screening of sleep apnea 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 10.1109/EMBC.2016.7591085, 978-1-4577-0220-4, (1870-1873) Arikawa T, Toyoda S, Haruyama A, Amano H, Inami S, Otani N, Sakuma M, Taguchi I, Abe S, Node K and Inoue T (2016) Impact of Obstructive Sleep Apnoea on Heart Failure with Preserved Ejection Fraction, Heart, Lung and Circulation, 10.1016/j.hlc.2015.09.011, 25:5, (435-441), Online publication date: 1-May-2016. Pan W, Su M, Wu H, Su T, Lin M and Sun C (2016) Multiscale entropic assessment of autonomic dysfunction in patients with obstructive sleep apnea and therapeutic impact of continuous positive airway pressure treatment, Sleep Medicine, 10.1016/j.sleep.2015.11.021, 20, (12-17), Online publication date: 1-Apr-2016. Chaudhari M, Fallavollita J, Farkas G and Fraidenraich D (2016) The Effects of Experimental Sleep Apnea on Cardiac and Respiratory Functions in 6 and 18 Month Old Dystrophic (mdx) Mice, PLOS ONE, 10.1371/journal.pone.0147640, 11:1, (e0147640) Tang X, Lin C, Guo D, Qian R, Li X, Shi Z, Liu J, Li X and Fan L (2016) CLOCK Promotes Endothelial Damage by Inducing Autophagy through Reactive Oxygen Species, Oxidative Medicine and Cellular Longevity, 10.1155/2016/9591482, 2016, (1-10), . Müller P, Grabowski C, Schiedat F, Shin D, Dietrich J, Mügge A, Deneke T, Walther J and Kara K (2016) Reverse Remodelling of the Atria After Treatment of Obstructive Sleep Apnoea with Continuous Positive Airway Pressure: Evidence from Electro-mechanical and Endocrine Markers, Heart, Lung and Circulation, 10.1016/j.hlc.2015.05.004, 25:1, (53-60), Online publication date: 1-Jan-2016. Alfille P, Wiener-Kronish J and Bagchi A (2016) Preoperative Evaluation Murray and Nadel's Textbook of Respiratory Medicine, 10.1016/B978-1-4557-3383-5.00027-0, (458-468.e3), . Carpenter A, Frontera A, Bond R, Duncan E and Thomas G (2015) Vagal atrial fibrillation: What is it and should we treat it?, International Journal of Cardiology, 10.1016/j.ijcard.2015.08.108, 201, (415-421), Online publication date: 1-Dec-2015. de Vries G, van der Wal H, Kerstjens H, van Deursen V, Stegenga B, van Veldhuisen D, van der Hoeven J, van der Meer P and Wijkstra P (2015) Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure, Journal of Cardiac Failure, 10.1016/j.cardfail.2015.06.009, 21:10, (848-855), Online publication date: 1-Oct-2015. Akyüz A, Akkoyun D, Değirmenci H and Alp R (2014) Atrial Fibrillation Is Associated With Increased Mean Platelet Volume and Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea, Angiology, 10.1177/0003319714548567, 66:6, (525-530), Online publication date: 1-Jul-2015. Asin J (2015) Behandeling van obstructieve slaapapneu, Bijblijven, 10.1007/s12414-015-0048-7, 31:6, (395-404), Online publication date: 1-Jul-2015. Cundrle I, Somers V, Johnson B, Scott C and Olson L (2015) Exercise End-Tidal CO 2 Predicts Central Sleep Apnea in Patients With Heart Failure, Chest, 10.1378/chest.14-2114, 147:6, (1566-1573), Online publication date: 1-Jun-2015. Pan W, Su M, Wu H, Lin M, Tsai I and Sun C (2015) Multiscale Entropy Analysis of Heart Rate Variability for
Referência(s)